![](/_assets/images/page-header-home-hcp-birds.webp)
![](/_assets/images/page-header-home-hcp-butterfly.webp)
![](/_assets/images/page-header-home-hcp-swing.webp)
![](/_assets/images/page-header-home-hcp-backpack.webp)
![](/_assets/images/page-header-home-hcp-sun.webp)
Little victories.
Big impact.
Lamzede is the first and only enzyme replacement therapy (ERT) approved for the treatment of non-central nervous system manifestations of alpha-mannosidosis, helping to reduce serum oligosaccharides and preserve endurance climbing stairs—because every extra step is in the right direction.1
Envision the impact Lamzede could make for your patients
![](/_assets/images/home-hcp-proven-pharmacodynamics.webp)
Proven pharmacodynamics
Helps mitigate the damage caused by the excess accumulation of mannose-rich oligosaccharides1,2
![](/_assets/images/home-hcp-walking-performance.webp)
May help with walking performance
Numerical trends show potential to improve walking performance as measured by the 6MWT1
![](/_assets/images/home-hcp-preserved-endurance.webp)
Preserved endurance climbing stairs
Helped patients maintain the ability to climb stairs, as measured by the 3MSCT3
![](/_assets/images/home-hcp-improved-pulmonary-function.webp)
May improve pulmonary function
Patients taking Lamzede showed favorable improvement in pulmonary function compared to those taking placebo1
3MSCT, 3-minute stair-climbing test; 6MWT, 6-minute walk test.
Why timely identification and treatment are key to helping mitigate the impact of alpha-mannosidosis4
Alpha-mannosidosis is an ultra-rare lysosomal storage disorder with a range of symptoms5-7
Learn aboutsigns & symptoms
Alpha-mannosidosis is challenging to identify and early diagnosis is key4
Learn aboutdiagnostic tools
Lamzede is designed to reduce mannose-rich oligosaccharides by supplementing the natural α-mannosidase enzyme1
Learn moreabout Lamzede